April 19, 2019
Novartis Pharma expects “around two to three” institutions in Japan to initially provide its CAR-T cell therapy Kymriah (tisagenlecleucel), but it hopes to gradually increase the number of certified sites that can offer the treatment with the highest standards, Japan...read more